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Abstract
Background: During the first decade following the coronary bypass grafting, at least ten percent of the 
patients require percutaneous coronary interventions (PCI) due to graft failure. Saphenous vein grafts 
(SVG) are innately at a higher risk of periprocedural complications. The present study aimed to inves-
tigate predictors of periprocedural complications of PCI within coronary artery bypass grafts. 
Methods: This study analyzed data gathered in the Polish National Registry (ORPKI) between January 
2015 and December 2016. Of the 221,195 patients undergoing PCI, data on 2,616 patients after PCI 
of SVG and 442 patients after internal mammary artery (IMA) were extracted. The dissimilarities in 
periprocedural complications between the SVG, IMA and non-IMA/SVG groups and their predictors 
were investigated. 
Results: Patients in the SVG group were older (p < 0.001), with a higher burden of concomitant 
disease and differing clinical presentation. The rate of de-novo lesions was lower, while restenosis was 
higher at baseline in the SVG (p < 0.001). The rate of no-reflows (p < 0.001), perforations (p = 0.01) 
and all periprocedural complications (p < 0.01) was higher in the SVG group, while deaths were lower 
(p < 0.001). Among the predictors of no-reflows, it was found that acute coronary syndromes (ACS), 
thrombectomy and past cerebral stroke, while the complications included arterial hypertension, Throm-
bolysis in Myocardial Infarction (TIMI) flow before PCI and thrombectomy.
Conclusions: Percutaneous coronary interventions of SVG is associated with increased risk of specific 
periprocedural complications. The ACS, slower TIMI flow before PCI and thrombectomy significantly 
increase the periprocedural complication rate in patients undergoing PCI of SVG. (Cardiol J 2019; 26, 
6: 633–644)
Key words: percutaneous coronary interventions, coronary artery by-passes,  
periprocedural complications, no-reflow, predictors
Introduction 
Within 10 years of coronary artery bypass 
graft surgery (CABG), even half of patients can 
be observed with graft failure [1]. Failed patency 
is usually caused by graft failure or a combination 
of graft failure and progression of coronary ath-
erosclerosis. Neointimal hyperplasia is considered 
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to be the main reason for the occlusion of venous 
grafts [2]. The optimal management of patients 
presenting with graft failure remains a subject of 
debate. Surgical reoperation is associated with 
high complication rates and mortality compared to 
conventional percutaneous coronary interventions 
(PCI) [3]. Also, repeat operations are associated 
with higher morbidity and mortality rates as well 
as poorer outcomes compared to initial operations 
[4]. Although endovascular treatment of saphenous 
vein grafts (SVGs) is connected with better results 
in comparison to re-CABG, there is still a great 
gap between PCI performed on native arteries 
and SVG, which reflects poorer results including 
higher in-hospital mortality among patients under-
going PCI of SVG [5]. Among several predictors 
of outcomes, the elevated markers of myocardial 
injury may translate into increased mortality when 
compared to patients with native vessel PCI [6]. 
Other variables which have been associated with 
increased risk of complications after PCI of SVG 
lesions include old, diffusely diseased, totally oc-
cluded grafts and grafts containing intraluminal 
thrombus with increased lesion friability and pro-
pensity for distal embolization [7]. 
The aim of the present study was to determine 
the procedural success, periprocedural complica-
tions and predictors of typical complications for 
SVG PCI in a consecutive series of patients un-
dergoing a non-staged SVG intervention in Poland 
in 2015 and 2016. 
Methods
Study population, design and definitions
Data from all patients who underwent PCI in 
Poland between January 2015 and December 2016 
were analyzed. Prospectively collected data on PCI 
practice in Poland were obtained from the ORPKI 
Polish National dataset, which is coordinated na-
tionwide by Jagiellonian University Medical Col-
lege in cooperation with AISN PTK (Association 
of Cardiovascular Interventions Polish Cardiac 
Society). Database characteristics and data collec-
tion methods have been previously presented [8, 
9]. Patients were categorized according to whether 
they had undergone PCI of SVG or the right/left 
internal mammary artery (IMA). PCI of all other 
coronary arteries, except SVGs and IMAs were 
included into the non-IMA/SVG group. All indices 
recorded in the ORPKI database are based on 
periprocedural data uploaded by the operator after 
each procedure. Therefore, they do not include 
all in-hospital complications, mainly those which 
occurred after the procedure until discharge from 
the hospital. Also, follow-up data after discharge 
was not collected due to lack of patient ID details. 
The decision to perform PCI of SVG or IMA was at 
the operators’ discretion at each center according 
to current guidelines [10]. All clinical decisions, 
such as vascular access, thrombectomy, treat-
ment with glycoprotein (GP) IIb/IIIa inhibitors 
or bivalirudin, were at the operators’ discretion. 
The definition of periprocedural complications in-
cluding death, perforation, dissection, myocardial 
infarction (MI), allergic reaction, cerebral stroke, 
puncture site bleeding, no-reflow or cardiac arrest 
remained to the operators’ personal preferences 
and knowledge [8].
Statistical analysis
All continuous variables were evaluated with 
the Kolmogorov-Smirnov test for distribution. 
Continuous variables are presented as mean ± 
± standard deviation and median ± interquartile 
range. Categorical variables are presented as 
numeric values and percentages. Continuous vari-
ables were compared using the two-tailed Student 
t-test and the Mann-Whitney U-test, whereas 
categorical variables used the c2 test. Statistical 
significance was accepted at a 0.05 level of prob-
ability. The statistical analyses were performed 
using Statistica 10.0 software (Dell Software, Inc, 
Round Rock, TX, USA) and SPSS STATISTICS 24 
(IBM, USA).
Multifactorial analysis 
Since the periprocedural complication rates in 
the IMA group of patients did not differ significantly 
from the non-IMA/SVG group when particular 
complications were compared, the present analysis 
concentrated on the comparison of the SVG and 
the non-IMA/SVG group. To identify predictors of 
all complications, no-reflows, deaths and perfora-
tions, univariate and multivariable analysis was 
performed. In this analysis, the following variables 
were tested in the SVG group: age, gender, dia-
betes, previous cerebral stroke, MI, PCI, CABG, 
smoking status, concomitant diseases including 
psoriasis, hypertension, kidney disease, chronic 
obstructive pulmonary disease, clinical presenta-
tion of coronary artery disease (CAD) at baseline 
(stable angina [SA] vs. acute coronary syndrome 
[ACS], SA vs. acute MI [AMI], SA vs. unstable 
angina [UA], UA vs. AMI), pharmacological treat-
ment before PCI and during PCI (acetylsalicylic 
acid [ASA], unfractionated heparin [UFH], low-mo-
lecular weight heparin [LMWH], P2Y12 inhibitors, 
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thrombolysis, GP IIb/IIIa inhibitors, bivalirudin), 
angiographic presentation of CAD (single-vessel 
disease [SVD] vs. others, left-main coronary artery 
[LMCA] involvement vs. others), vascular access 
(radial vs. femoral), fractional flow reserve (FFR), 
intravascular ultrasound (IVUS), optical coherent 
tomography (OCT), thrombectomy, pharmacologi-
cal treatment, Thrombolysis in Myocardial Infarc-
tion (TIMI) flow before PCI (1–2 vs. 2–3), contrast 
dose and radiation exposition, PCI of chronic total 
occlusions (CTO) or bifurcation, stent implantation, 
drug-eluting stent (DES) implantation, number of 
implanted DES stents (1 vs. 2 or more stents), 
bare-metal stent (BMS) implantation, number of 
implanted stents regardless of type (1 vs. 2 or more 
stents), bioresorbable scaffold (BRS) implantation, 
PCI with drug-coated balloon (DCB) and PCI with 
DCB/plain old balloon angioplasty (POBA)/failed. 
Also performed were univariate and multivariable 
analysis of potential predictors of all complications, 
no-reflows, deaths and perforations in the overall 
group of patients. In this analysis, rotablations 
(RAs),  were additionally included. 
Results
General characteristics
The general characteristics of patients exam-
ined in the current study including concomitant 
diseases, past cardiovascular procedures, gender 
and age in the assessed groups of patients and 
according to PCI of SVG and IMA are presented 
in Table 1. 
Clinical presentation, coronary  
angiography and vascular access
The clinical presentations of CAD included 
SA, UA, non-ST-segment elevation MI (NSTEMI), 
ST-segment elevation MI (STEMI), AMI or others 
where such indications like cardiac arrest or valvu-
lar diseases were included. Coronary angiography 
was divided into four groups: SVD, multi-vessel 
disease (MVD) without LMCA involvement, MVD 
with LMCA involvement and isolated LMCA in-
volvement. Vascular access was assessed as femo-
ral access, right and left radial access and others. 
All the above-mentioned indices were compared 
in three separate groups: non-IMA/SVG group, 
IMA and SVG group and are presented in Table 1. 
Procedural variables
Selected procedural indices were compared 
which involved procedural contrast dose, radiation 
exposition, use of FFR, IVUS and OCT, type of le-
sion undergoing PCI including CTO, bifurcations, 
type of the procedure with stent type (BMS, DES, 
BRS, DCB, POBA or failed PCI) and the use of 
additional devices such as RA or thrombectomy in 
three separate groups of patients: non-IMA/SVG 
group, SVG and IMA group. This is presented in 
Table 2. 
Pharmacological treatment
Pharmacological treatment was also compared 
before and during PCI between three selected 
groups of patients including non-IMA/SVG group, 
IMA and SVG group, which was presented in Table 2. 
Among the assessed pharmaceutics, there were 
antiplatelet agents, heparins, thrombolysis and bi-
valirudin. This comparison is presented in Table 3. 
Culprit lesion characteristics
Also distinguished and compared were the 
type and frequency of culprit lesion undergoing 
PCI in the selected three groups of patients which 
included de-novo rates, restenosis rates, and in-
stent thrombosis rate. The restenosis rate was 
also divided into BMS, DES, BRS, DCB and POBA 
restenosis. In general, the frequency of the de-novo 
lesions was lower in the SVG group as compared to 
the non-IMA/SVG group (p < 0.001), and was also 
lower when compared to IMA group (p < 0.001). 
Whereas, the rate of restenosis was higher in 
the IMA (p = 0.02) and SVG group (p < 0.001) 
compared to the non-IMA/SVG group. Moreover, 
the rate of restenosis in the SVG PCI group was 
significantly higher when compared to IMA group 
(p < 0.001). The rate of in-stent thrombosis did 
not differ significantly between groups. However, 
it was highest in the SVG PCI group (0.7%). All 
indices are presented in Table 4. 
Periprocedural complications
The periprocedural complications included 
those which occurred in the operating room and 
do not cover all complications which took place 
during subsequent days of hospitalization. the 
Death rates, cerebral strokes, MI, dissections, 
no-reflows, puncture site bleedings, allergic reac-
tions and perforations in the non-IMA/SVG group 
as well as the IMA and SVG groups were assessed. 
Overall complication rate per patient and per 
complication in all above-mentioned groups were 
also compared. Overall complication rates reached 
1.92% when assessed per patient and 2.29% when 
assessed per complication in the non-IMA/SVG 
group of patients and was significantly higher in 
SVG group compared to non-IMA/SVG group for 
www.cardiologyjournal.org 635
Rafał A. Januszek et al., PCI of coronary bypasses and periprocedural complications 
both estimations (2.63% vs. 1.92%, p = 0.008 
and 3.09% vs. 2.29%, p = 0.007). It did not dif-
fer significantly between PCI IMA and non-IMA/ 
/SVG groups, while the difference was significant 
between IMA and SVG group (1.58 vs. 3.09, p = 
= 0.02) for overall complication rate and was low-
est in IMA group. The periprocedural mortality 
rate was the lowest in IMA group compared to 
the SVG and non-IMA/SVG group, however it did 
not reach statistical significance (0.22% vs. 0.34% 
vs. 0.46%, respectively). No-reflows were more 
frequent in SVG group compared to non-IMA/SVG 
group (1.37% vs. 0.51%, p < 0.001) and IMA-group 
(1.37 vs. 0.44, p = 0.01). Also, perforation rate was 
significantly higher in SVG subgroup compared to 
non-IMA/SVG PCI group (0.38% vs. 0.17%, p = 
= 0.01). There were no perforations noticed in IMA 
group of patients. No significant differences were 
noticed in rates of other complications between 
selected subgroups of patients. The distribution of 
particular complication rates in selected subgroups 
is presented in Figure 1A. 
Procedural effectiveness
In IMA group, periprocedural effectiveness 
assessed as TIMI flow 2–3 after the procedure com-
pared to non-IMA/SVG group (96.1% vs. 96.8%, 
p = 0.46), while in SVG group, it was significantly 
Table 1. Baseline characteristics. 
Variable PCI non- 
-IMA/SVG 
(n = 218,137)
PCI IMA 
(n = 442)
P 
Non-IMA/ 
/SVG vs. IMA
PCI SVG 
(n = 2,616)
P  
Non-IMA/ 
/SVG vs. SVG
P 
SVG vs.  
IMA
Age [years] 67.0 ± 10.8 68.9 ± 9.7 < 0.001 70.5 ± 8.9 < 0.001 < 0.001
Gender, males 147,749 (67.7%) 339 (76.7%) < 0.001 2,059 (78.7%) < 0.001 0.34
Diabetes 51,720 (23.7%) 135 (30.5%) < 0.001 822 (31.4%) < 0.001 0.71
Hypertension 154,999 (71.0%) 337 (76.2%) 0.01 2,079 (79.5%) < 0.001 0.12
COPD 5,512 (2.5%) 11 (2.5%) 0.95 71 (2.7%) 0.54 0.78
Cerebral stroke 7,156 (3.3%) 18 (4.1%) 0.35 116 (4.4%) 0.001 0.73
Myocardial infarction 67,106 (30.8%) 255 (57.7%) < 0.001 1,596 (61%) < 0.001 0.18
PCI 80,685 (37.0%) 240 (54.3%) < 0.001 1,522 (58.2%) < 0.001 0.12
Smoking 42,251 (19.4%) 45 (10.2%) < 0.001 278 (10.6%) < 0.001 0.77
Kidney failure 11,820 (5.4%) 36 (8.1%) 0.01 273 (10.4%) < 0.001 0.13
Clinical presentation:
Stable angina 60,356 (27.7%) 114 (25.8%) 0.36 583 (22.3%) < 0.001 0.1
Unstable angina 64,459 (29.6%) 191 (43.2%) < 0.001 1,070 (40.9%) < 0.001 0.36
NSTEMI 40,371 (18.5%) 80 (18.5%) 0.81 667 (25.5%) < 0.001 < 0.001
STEMI 50,787 (23.3%) 54 (12.2%) < 0.001 273 (10.4%) < 0.001 0.26
Others 1,833 (0.8%) 3 (0.67%) 0.94 23 (0.9%) 0.83 0.99
Vascular access:
AMI 91,158 (41.8%) 134 (29.9%) < 0.001 940 (35.9%) < 0.001 0.02
Radial right 125,559 (57.6%) 47 (10.6%) < 0.001 524 (20.0%) < 0.001 < 0.001
Radial left 35,974 (16.5%) 149 (33.7%) < 0.001 661 (25.3%) < 0.001 < 0.001
Femoral 55,007 (25.2%) 237 (53.6%) < 0.001 1,394 (53.3%) < 0.001 0.89
Coronary angiography:
Other 1,597 (0.7%) 9 (2.0%) 0.001 37 (1.4%) < 0.001 0.32
SVD 137,080 (69.2%) 235 (58.4%) < 0.001 1,387 (56.8%) < 0.001 < 0.001
MVD, LMCA (–) 51,412 (26.0%) 128 (31.8%) 0.007 723 (29.6%) < 0.001 0.37
MVD, LMCA (+) 7,736 (3.9%) 38 (9.4%) < 0.001 326 (13.4%) < 0.001 0.02
Isolated LMCA 1,814 (0.9%) 1 (0.2%) 0.16 4 (0.2%) < 0.001 0.7
Data given as mean ± standard deviation or number and percentages. P-value by c2 test for categorical variables. T-test for continuous  
variables. AMI — acute myocardial infarction; COPD — chronic obstructive pulmonary disease; LMCA — left-main coronary artery;  
MVD — multi-vessel disease; NSTEMI — non-ST-segment elevation myocardial infarction; PCI — percutaneous coronary intervention;  
STEMI — ST-segment elevation myocardial infarction; SVD — single-vessel disease
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Table 2. Procedural variables. 
Variable PCI non-  
-IMA/SVG 
(n = 218,137)
PCI IMA 
(n = 442)
P 
Non-IMA/ 
/SVG vs. IMA
PCI SVG 
(n = 2,615)
P 
Non-IMA/ 
/SVG vs. SVG
P 
IMA vs.  
SVG
Type of PCI:
BMS 7,209  (3.3%) 6 (1.35%) 0.02 56 (2.14%) < 0.001 0.27
DES 187,042  (85.7%) 357 (80.7%) 0.002 2,155 (82.4%) < 0.001 0.4
BRS 2,925 (1.3%) 3 (0.67%) 0.22 5 (0.19%) < 0.001 0.06
DCB 4,708 (2.1%) 9 (2.0%) 0.86 117 (4.47%) < 0.001 0.01
POBA/failed 16,253 (7.4%) 67 (15.1%) < 0.001 282 (10.8%) < 0.001 0.007
Rotablation 974 (0.4%) 0 (0%) 0.15 1 (0.03%) 0.001 0.68
Thrombectomy 7,001 (3.2%) 10 (2.26%) 0.25 114 (4.35%) < 0.001 0.03
Bifurcation 11,803 (5.4%) 55 (12.4%) < 0.001 37 (1.41%) < 0.001 < 0.001
CTO 9,235 (4.2%) 52 (11.8%) < 0.001 34 (1.3%) < 0.001 < 0.001
OCT 392 (0.2%) 0 (0%) 0.37 8 (0.3%) 0.13 0.24
IVUS 1,876 (0.9%) 0 (0%) 0.05 6 (0.22%) < 0.001 0.31
FFR 3,248 (1.5%) 3 (0.7%) 0.15 7 (0.26%) < 0.001 0.16
Contrast [mL] 175.6 ± 78.5 224.3 ± 108.0 < 0.001 217.78 ± 93.9 < 0.001 0.19
Radiation [Gy] 1,069.5 ± 963.6 1,204.3 ± 1048.4 0.005 1,216.5 ± 1058.8 < 0.001 0.83
Data given as mean ± standard deviation or number and percentages. P-value by c2 test for categorical variables. T-test for continuous variables. 
BMS — bare-metal stent; BRS — bioresorbable scaffold; CTO — chronic total occlusion; DCB — drug-coated balloon; DES — drug-eluting 
stent; FFR — fractional flow reserve; IVUS — intravascular ultrasound; OCT — optical coherence tomography; POBA — plain old balloon  
angioplasty
Table 3. Pharmacological treatment. 
Medication PCI non- 
-IMA/SVG 
(n = 218,137)
PCI IMA 
(n = 442)
P 
Non-IMA/ 
/SVG vs. IMA
PCI SVG 
(n = 2,616)
P 
Non-IMA/ 
/SVG vs. SVG
P 
SVG  
vs. IMA
Pharmacotherapy before PCI
Acetylsalicylic acid 106,921 (49.0%) 174 (39.4%) < 0.001 1,281 (49.0%) 0.96 < 0.001
Unfractionated heparin 32,414 (14.8%) 44 (9.9%) 0.003 314 (12.0%) < 0.001 0.21
LMWH 2,030 (0.9%) 1 (0.2%) 0.12 30 (1.1%) 0.25 0.07
P2Y12 inhibitors
Clopidogrel 120,066 (55.0%) 213 (48.2%) 0.003 1,532 (58.6%) < 0.001 < 0.001
Ticagrelor 10,988 (5.0%) 24 (5.4%) 0.7 122 (4.7%) 0.38 0.48
Prasugrel 1,157 (0.5%) 2 (0.4%) 0.82 6 (0.2%) 0.03 0.39
GP IIb/IIIa inhibitors 21,066 (11.8%) 42 (11.9%) < 0.001 395 (17.5%) < 0.001 0.008
Bivalirudin 17 (0.007%) 0 (0%) 0.85 0 (0%) 0.65 -
Thrombolysis 44 (0.02%) 0 (0%) 0.74 0 (0%) 0.42 -
Pharmacotherapy during PCI
Acetylsalicylic acid 36,977 (16.9%) 63 (14.2%) 0.13 495 (18.9%) 0.007 0.01
Unfractionated heparin 183,913 (84.3%) 359 (81.2%) 0.07 2,309 (88.3%) < 0.001 < 0.001
LMWH 8,419 (3.8%) 22 (5.0%) 0.22 65 (2.5%) < 0.001 0.003
P2Y12 inhibitors
Clopidogrel 91,783 (42.1%) 181 (40.9%) 0.63 1,124 (43.0%) 0.35 0.42
Ticagrelor 10,213 (4.7%) 20 (4.5%) 0.87 126 (4.8%) 0.74 0.79
Prasugrel 990 (0.4%) 2 (0.4%) 0.99 14 (0.5%) 0.53 0.82
GP IIb/IIIa inhibitors 836 (0.4%) 3 (0.7%) 0.31 10 (0.4%) 0.91 0.4
Bivalirudin 566 (0.2%) 0 (0%) 0.28 4 (0.1%) 0.28 0.41
Thrombolysis 344 (0.1%) 2 (0.4%) 0.11 3 (0.1%) 0.58 0.1
Data given as number and percentage. P-value by c2 test. GP — glycoprotein; LMWH — low molecular weight heparin
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lower when compared to non-IMA/SVG group 
(93.8% vs. 96.8%, p < 0.001). The effectiveness 
of PCI SVG assessed by the TIMI scale was also 
poorer in PCI SVG group compared to non-IMA/ 
/SVG PCI group after PCI and separation into 
TIMI 0 group (5% vs. 2.25%, p < 0.001) and 
TIMI 4 group (90.3% vs. 94.1%, p < 0.001). The 
TIMI flow distributions in selected groups of pa-
tients according to TIMI grade before and after PCI 
are presented in Figure 1B. 
Predictors of selected periprocedural  
complications in non-IMA/SVG group
Among significant independent predictors of 
increased rate of all complications in non-IMA/ 
/SVG group of patients, the following distinctions 
were made: age, gender, diabetes, past cerebral 
stroke, past MI, kidney failure, ACSs, PCI of 
patients with coronary angiography image other 
than SVD, femoral access, thrombectomy, RA and 
cardiac arrest, while among predictors of lower rate 
of periprocedural complications, also found were: 
past CABG and patent coronary artery before PCI 
expressed as TIMI flow 2–3 (Fig. 2A).
Independent predictors of the higher rate of 
no-reflows in non-IMA/SVG group of patients as-
sessed by multivariable analysis included age, past 
cerebral stroke, past MI, smoking, hypertension, 
AMI, other angiographic image than SVD, femoral 
access and thrombectomy, while among predictors 
of lower rate of no-reflows patent artery before 
PCI expressed as TIMI flow 2–3 (Fig. 2B) was 
also found.
In non-IMA/SVG group of patients, it was 
found that age, diabetes, past cerebral stroke, 
past MI, kidney failure, ACSs, other angiographic 
image than SVD, femoral access, thrombectomy, 
and cardiac arrest to be among the independent 
predictors of an increased rate of death, while for 
predictors of decreased risk of periprocedural death 
the following was confirmed: male gender, past 
CABG, hypertension and patent artery before PCI 
expressed as TIMI flow 2–3 (Fig. 3A). 
Among independent predictors of increased 
risk of procedural perforations in non-IMA/SVG 
group of patients undergoing PCI assessed in 
multivariable analysis included the following: age, 
hypertension, other than single vessel CAD in 
angiography, PCI of coronary arteries other than 
LMCA, RA and cardiac arrest, while decreased risk 
predictors included male gender and TIMI flow 2–3 
before PCI (Fig. 3B). 
Predictors of selected periprocedural  
complications assigned to the SVG group
Considering all complication rates, the multi-
variable analysis revealed hypertension (odds ratio 
[OR]: 4.4, 95% confidence interval [CI]: 1.05–18.5, 
p = 0.04) and thrombectomy (OR: 3.3, 95% CI: 
1.4–7.6, p = 0.005) as predictors of increased rate 
of all periprocedural complications while among 
predictors of decreased rate of death, TIMI flow 
2–3 before PCI (OR: 0.4, 95% CI: 0.2–0.8, p = 
= 0.01) in the SVG group was distinguished. Among 
predictors of increased rate of no-reflows in SVG 
group assessed by multivariable analysis, these 
Table 4. Characteristics of culprit lesion.
Variable PCI non-  
-IMA/SVG 
(n = 241,234)
PCI IMA 
(n = 493)
P 
Non-IMA/ 
/SVG vs. 
IMA
PCI SVG 
(n = 2,779)
P 
Non-IMA/ 
/SVG vs. 
SVG
P 
SVG vs.  
IMA
Number of patients 218,137 (100%) 442 (0.2%) – 2,616 (1.2%) – –
Overall lesions count 241,234 (100%) 493 (0.2%) – 2,779 (1.1%) – –
De-novo lesions 228,971 (94.9%) 459 (93.1%) 0.06 2,378 (85.6%) < 0.001 < 0.001
Restenosis (overall) 11,065 (4.6%) 33 (6.7%) 0.02 380 (13.7%) < 0.001 < 0.001
Drug-eluting stent restenosis 7,447 (3.1%) 25 (5.1%) 0.01 309 (11.1%) < 0.001 < 0.001
Bare-metal stent restenosis 3,120 (1.3%) 4 (0.8%) 0.34 45 (1.6%) 0.13 0.17
Bioresorbable scaffold restenosis 134 (0.05%) 1 (0.2%) 0.16 8 (0.3%) < 0.001 0.73
Drug-coated balloon restenosis 107 (0.04%) 1 (0.2%) 0.09 7 (0.2%) < 0.001 0.83
Plain-old balloon angioplasty 
restenosis
257 (0.1%) 2 (0.4%) 0.04 11 (0.4%) < 0.001 0.97
In-stent thrombosis 1,198 (0.5%) 1 (0.2%) 0.35 21 (0.7%) 0.054 0.16 
Data given as number and percentage. P-value by c2 test.
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were found: past cerebral stroke (OR: 3.3, 95% 
CI: 1.0–10.4, p = 0.04), ACSs (OR: 5.5, 95% CI: 
1.2–23.9, p = 0.02) and thrombectomy (OR: 4.4, 
95% CI: 1.7–11.4, p = 0.002). Multivariable analy-
sis did not reveal any significant predictors of death 
in the group of patients undergoing PCI of SVG. 
The only significant predictor of perforation in the 
group of patients undergoing PCI of SVG was male 
gender (OR: 0.17, 95% CI: 0.04–0.8, p = 0.02). 
Discussion
 The current study confirmed the significant 
separateness of PCI performed within SVGs when 
compared to native arteries in terms of several in-
dices such as coronary angiography image, clinical 
presentation of CAD, culprit lesion characteristics 
or concomitant diseases, age and gender. This along 
with many other factors involved, also determines 
the different panel of predictors of periprocedural 
complications and their type. The greatest differ-
ences in the incidence of periprocedural complica-
tions, because of the similarity of PCIs performed 
on internal mammary arteries to native coronary 
arteries, were noticed in patients undergoing PCIs 
of SVGs, and they included an increased rate of 
all periprocedural complications, no-reflows and 
perforations. Furthermore, considering significant 
Figure 1. A. The distribution of Thrombolysis in Myocardial Infarction (TIMI) flow grades before and after percutane-
ous coronary interventions (PCI) expressed as percentages in the non-internal mammary artery (IMA)/saphenous vein 
grafts (SVG) group, IMA and SVG groups of patients undergoing PCI; B. The distribution of periprocedural complica-
tions expressed as percentages in the non-IMA/SVG group, IMA and SVG groups of patients undergoing PCI.
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predictors of periprocedural complications as-
sessed using multivariable analysis, their number 
was much smaller and was limited to more specific 
factors among which, and the most deserving of 
them, included clinical presentation of CAD, TIMI 
flow before PCI, use of thrombectomy and gender. 
Figure 2. A. Predictors of all periprocedural complications assessed by multivariable analysis in the overall group of 
patients undergoing percutaneous coronary interventions (PCI); B. Predictors of no-reflows assessed by multivariable 
analysis in the overall group of patients undergoing PCI; ACS — acute coronary syndrome; AMI — acute myocardial 
infarction; SA — stable angina; CABG — coronary artery bypass grafting; CI — confidence interval; OR — odds ratio; 
SVG — saphenous vein grafts; TIMI — Thrombolysis in Myocardial Infarction.
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Figure 3. A. Predictors of deaths assessed by multivariable analysis in the overall group of patients undergoing 
percutaneous coronary interventions (PCI); B. Predictors of perforations assessed by multivariable analysis in the 
overall group of patients undergoing PCI; ACS — acute coronary syndrome; AMI — acute myocardial infarction; 
SA — stable angina; CABG — coronary artery bypass grafting; CI — confidence interval; LMCA — left-main coronary 
artery; OR — odds ratio; SVG — saphenous vein grafts; TIMI — Thrombolysis in Myocardial Infarction.
www.cardiologyjournal.org 641
Rafał A. Januszek et al., PCI of coronary bypasses and periprocedural complications 
9
9 11 13
–1
–1
–3
–3
1
1
3
3
7
7
5
5
OR        95% Cl             P-value
OR              95% Cl          P-value
Age 
Gender 
Diabetes 
Past cerebral stroke 
Past myocardial infarction 
Past CABG 
Hypertension 
Kidney failure 
SA vs. ACS 
SVD vs. others 
Radial vs. femoral access 
Thrombectomy 
TIMI ow before PCI 
Cardiac arrest 
1.034 1.027–1.040 < 0.001
0.639 0.514–0.793 < 0.001
1.528 1.303–1.791 < 0.001
1.575 1.213–2.044      0.001
1.375 1.126–1.678      0.002
0.333 0.230–0.482 < 0.001
0.570 0.491–0.660 < 0.001
1.427 1.131–1.801      0.003
5.213 3.447–7.884 < 0.001
1.764 1.497–2.077 < 0.001
3.039 2.628–3.514 < 0.001
1.419 1.127–1.787      0.003
0.269 0.227–0.318 < 0.001
6.055 5.073–7.227 < 0.001
Age 
Gender 
Hypertension 
SVD vs. others 
LMCA vs. others 
Rotablation 
TIMI ow before PCI 
Cardiac arrest 
1.014 1.004–1.024 0.007
0.712 0.571–0.886 0.002
1.354 1.051–1.745 0.02
1.278 1.011–1.616 0.04
1.507 1.007–2.256 0.04
5.457 2.557–11.646 < 0.001
0.648 0.523–0.802 < 0.001
1.846 1.029–3.312 0.04
A
B
Considering past CABG procedure, patients 
in the IMA and SVG groups are older, more of-
ten males and more frequently burdened with an 
accompanying disease such as diabetes, kidney 
failure or hypertension. The higher incidence of 
atherosclerosis risk factors is associated with more 
advanced atherosclerosis in this selected group of 
patients. Interestingly, the incidence of chronic 
obstructive pulmonary disease was similar when 
comparing all three groups, while there were less 
smokers in the group of patients undergoing PCI 
IMA and SVG compared to the non-IMA/SVG 
group. This could be explained by the fact that 
CABG procedure is a motivating factor for smok-
ing cessation. Also, the higher rate of peracted 
MIs and PCIs in IMA and SVG group compared to 
non-IMA/SVG group is undoubtedly related to the 
peracted CABG procedure. A similar relationship 
may be an explanation for the higher prevalence of 
MVD in IMA and SVG groups. Similarly, a higher 
incidence of UA in IMA and SVG groups compared 
to non-IMA/SVG group, and lower frequency of 
STEMI and NSTEMI is associated with the pres-
ence of a more complicated cardiac vascularization 
system and associated vascular disorders like the 
steal syndrome. PCI procedures in patients after 
CABG are much more frequently performed with 
femoral access, due to the fact that radial access 
in many cases prevents even intubation of the 
culprit vessel.
Among predictors of periprocedural complica-
tion specific for PCI of SVGs, studies published to 
date have revealed increased intraluminal pres-
sure, graft wall ischemia, thrombosis, fibrin depo-
sition or trauma, secondary repair as well as graft 
age [11]. For example, Cicek et al. [12] published 
a study which included 48 patients at a mean age 
of 62 years, 92% were men. Indications for revas-
cularization included SA in 71% of patients, UA in 
23% and AMI in 6%. Stent deployment was per-
formed in all patients. The GP IIb/IIIa inhibitor was 
used in 56% patients. No-reflow, defined as TIMI 1 
flow, was observed in 2 patients and slow flow, 
defined as TIMI 2 flow, was observed in 3 patients. 
Overall, no reflow/slow flow phenomenon occurred 
in 10% of patients (n = 4, 2 patients with UA and 
2 patients with AMI), which was higher compared 
to the present group. Angiographic success was 
achieved in 98% of patients, which was also higher 
compared to the present group when TIMI flow 2 
and 3 was assumed as angiographic success (94%). 
All patients survived after stent implantation, but 
2 patients experienced non Q-wave MI and 1 patient 
experienced Q wave MI [12]. No relation between 
no reflow/slow flow and GP IIb/IIIa inhibitor use, 
hypercholesterolemia or lesion length was found 
[12]. Another study, which presented procedural 
results of multiple SVG stenting demonstrated 
distal embolization in 3.4% of patients in the single 
SVG group and in 0.9% of patients in the multiple 
SVG group [13]. Furthermore, a study performed 
on 51 patients who underwent stenting of the 
bypass graft demonstrated distal embolization 
in 13.6% of PCIs [14]. They also reported lower 
rates of non-Q MIs in patients treated with stent 
implantation compared to POBA (2% vs. 7%). The 
procedural success rate after SVG stenting in this 
study was 97% [15]. Sdringola et al. [16] detected 
four independent risk factors for the no reflow/slow 
flow phenomenon as probable thrombus, ACSs, 
degenerated vein graft and ulcerated plaque. All of 
this data was not compared, however ACSs were 
similar predictors of an increased rate of peripro-
cedural no-reflows in patients undergoing PCI of 
SVG. It was also demonstrated that past cerebral 
stroke was an independent predictor of increased 
rate of no-reflows. One possible explanation is 
that patients after cerebral stroke are usually im-
mobilized to some degree, which decreases hemo-
dynamic response of the cardiovascular system 
on stress. Consequently, it is related to impaired 
endothelial response and increased thrombogenic-
ity. The PAMI-2 trial comparing the effectiveness 
of PCI in patients with grafts and native coronary 
arteries were revealed among predictors AMI and 
PCI of native coronary arteries. The procedural 
success assessed as TIMI flow grade 3 was lower 
in graft PCI (70%) compared to native arteries 
(94%). The reason for this difference was explained 
by authors as due to extensive thrombus, athero-
sclerosis burden in bypass grafts and increased rate 
of distal embolization [17]. However, they did not 
confirm the relationship between distal emboliza-
tion and GP IIb/IIIa inhibitor use. Other authors 
have shown that GP IIb/IIIa inhibitors reduce 
thrombus burden in SVG lesions and may decrease 
distal embolization during PCI [18]. In the above-
mentioned studies, the study group was small and 
GP IIb/IIIa inhibitor use was limited. They were 
unable to definitively conclude that GP IIb/IIIa in-
hibitors reduced distal embolization. Based on our 
data, univariate analysis confirmed the significant 
relationship between treatment with GP IIb/IIIa 
inhibitors before and during PCI and the rate of 
periprocedural deaths, no-reflows and all complica-
tion counts in the overall group of patients undergo-
ing PCI (p < 0.001 in all comparisons). However, 
multivariable analysis did not confirm such a re-
642 www.cardiologyjournal.org
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lationship. Similar univariate analysis performed 
in the SVG group revealed only the relationship 
between no-reflows and overall complication rates 
for treatment with GP IIb/IIIa inhibitors before 
PCI, but not after it. Also, multivariable analysis 
did not confirm those relationships. Large-scale, 
randomized studies should be performed to clarify 
this. Another abovementioned study revealed that 
after stenting of SVG, the lesion length and total 
cholesterol levels were independent predictors 
of distal embolization [14]. The present study did 
not possess this kind of data except for hyper-
cholesterolemia, which was not an independent 
predictor of periprocedural complications. Kuroda 
et al. [14] did not observe any no reflow/slow flow 
during PCI of in-stent restenosis lesions of SVGs. 
In SVG group from the present study, target lesions 
were significantly more often restenosis and less 
frequently de-novo lesions compared to non-IMA/ 
/SVG group. Univariate analysis did not reveal any 
relationships between particular periprocedural 
complications and the presence of restenosis. On 
the contrary, in-stent thrombosis rate was signifi-
cantly associated with increased death rate (p < 
< 0.001) and overall complication rate (p = 0.04) 
in univariate analysis. In-stent restenosis lesions 
are pathologically distinct from de novo lesions. 
In degenerated SVGs, de novo lesions had friable 
atherogenic material. Bhargava et al. [13] compared 
two group of patients undergoing PCI of SVG in 
SVD and MVD groups. The overall angiographic 
and procedural success rates were similar in both 
groups. Similarly, major in-hospital complications 
including death, Q wave MI and emergent CABG 
were similar in the single stent SVG and multiple 
stent SVG groups (2.7% and 2.8%). However, the 
periprocedural non Q wave MI rate defined as 
creatinine kinase-MB > 5 times above the norm 
was significantly higher in SVG group (28% vs. 
16%). The frequency of GP IIb/IIIa inhibitor use did 
not differ significantly between both investigated 
groups and was higher in the multiple stent group 
(4% vs. 6.5%) [13]. Porto et al. [19] confirmed that 
the use of post-dilatation was significantly higher in 
the group of patients who subsequently developed 
filter no-reflow (57% vs. 26%, p = 0.04). In the 
presented study it was found, that hypertension 
was an independent predictor of increased rate of 
overall complications count in SVG group. At the 
same time it was observed that in the SVG group, 
hypertension correlated positively with increased 
rate of no-reflows (p = 0.02, r = 0.04) and cardiac 
arrests (p = 0.04, r = 0.03). This could, at least in 
part explain this relationship. It was also noticed 
that the only independent predictor of coronary 
artery perforation during PCI of SVG was male 
gender. This is not in line with previously published 
results performed on the overall group of patients 
treated with PCI, where female gender was found 
to be an independent predictor of increased rate 
of periprocedural perforations [20]. Additionally, 
in the current study males in SVG group were 
significantly younger compared to females, which 
additionally raises some questions. 
Limitations of the study
First of all, this is rather a study based on 
the nationwide volunteer registry rather than 
a prospective randomized clinical trial. This tends 
to decrease and underestimate the detection of 
periprocedural complication rate and other crucial 
variables which are dependant on a subjective as-
sessment of the operator, despite a large overall 
interventional volume included in the present 
analysis. Furthermore, the current analysis does 
not include all in-hospital complications which 
undoubtedly weakens its value. The lack of data 
evaluating the process of neointimal hyperplasia in 
the present study, such as intravascular ultrasound 
or OCT, makes it impossible to assess the relation-
ship between the analyzed risk factors and the type 
and severity of processes leading to occlusion of 
evaluated bypasses. Undoubtedly, an advantage of 
the current study is that the results are closer to 
real life rather than to randomized clinical trials 
and shows clinical data depicting the results of 
SVG PCIs in Central Europe. 
Conclusions
The group of patients undergoing PCI of SVG 
is at increased risk of periprocedural complications. 
Among the periprocedural complications typical for 
PCI of SVG, the following was distinguished: death, 
no-reflow, perforation and overall periprocedural 
complication count. Also, the panel of independ-
ent predictors of periprocedural complications is 
different in patients undergoing PCI of SVG com-
pared to non-IMA/SVG, and in the current study, 
for selected factors it included male gender, ACS, 
thrombectomy, TIMI flow before PCI, past cerebral 
stroke and hypertension.  
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